Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech, FDA Discussing Herceptin Label Changes To Reflect New PK Data

Executive Summary

Genentech and FDA are discussing updates to Herceptin labeling following the submission of preliminary data suggesting the half-life of trastuzumab is up to five times longer than previously thought.

You may also be interested in...



Genentech Will Focus On Pipeline For Near-Term Growth, CEO Says

Genentech's near-term growth will be based on its product pipeline rather than through acquisitions, CEO Arthur Levinson, PhD, told analysts during the company's fourth quarter earnings call Jan. 16

Genentech Will Focus On Pipeline For Near-Term Growth, CEO Says

Genentech's near-term growth will be based on its product pipeline rather than through acquisitions, CEO Arthur Levinson, PhD, told analysts during the company's fourth quarter earnings call Jan. 16

Genentech Xanelim Therapy Transition Study To Support Product Launch

Genentech plans to generate data on transitioning patients from its psoriasis therapy Xanelim to other products to assist with efalizumab promotions upon approval.

Related Content

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel